Appl. No. 09/674,616

Amdt. Dated: February 3, 2005

Reply to Office action of October 6, 2004

## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claims 1-19 (canceled)

20 (new):

A compound of formula:

Y-(CR<sub>2</sub>)<sub>n</sub>-X-NHJ

where:

X is C=O or  $CR_2$ ;

n is an integer of value 1 to 6;

Y is R<sup>1</sup>R<sup>2</sup>CR- where one of R<sup>1</sup> and R<sup>2</sup> is -NH(B)<sub>p</sub>Z<sup>1</sup> and the other

is  $-CO(B)_aZ^2$  where

p and q are integers of value 0 to 30, and

each B is independently chosen from Q or an amino acid residue,

where Q is a cyclic peptide;

 $Z^1$  and  $Z^2$  are metal complexing agents (L) or other protecting groups, which are biocompatible groups which inhibit or suppress *in vivo* metabolism of the peptide; J and each R group are independently chosen from H,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkenyl,  $C_{1-4}$  alkoxyalkyl or  $C_{1-4}$  hydroxyalkyl;

with the provisos that:

- (i) the total number of amino acid residues in the R<sup>1</sup> and R<sup>2</sup> groups does not exceed 30;
- (ii) when X is  $CR_2$ , then  $Z^2$  is a metal complexing agent (L);
- (iii) at least one of R<sup>1</sup> and R<sup>2</sup> bears at least one detectable moiety suitable for diagnostic imaging of the human body;
- (iv)  $R^1$  and  $R^2$  include one or more of the sequences NQEQVSPYTLLKG (SEQ ID NO: 2), which is a peptide fragment of  $\alpha_2$ -antiplasmin.

21(new): The compound of claim 20 where the amino acid in the 2-position from the

Appl. No. 09/674,616

É.

Amdt. Dated: February 3, 2005

Reply to Office action of October 6, 2004

peptide N-terminus is glutamine.

22(new): The compound of claim 20 where J is H.

23 (new): The compound of claim 22 of formula:

 $Y-(CR_2)_x-(CH_2)_2CONH_2$  or  $Y-(CR_2)_y-(CH_2)_4NH_2$ 

where x is an integer of value 0 to 4, and y is an integer of value 0 to 3.

24 (new): The compound of claim 20 where at least one of  $Z^1$  and  $Z^2$  is a metal complexing agent.

25 (new): The compound of claim 24 where  $Z^2$  is a metal complexing agent and  $Z^1$  is not a metal complexing agent.

26 (new): A metal complex of the compound of claim 24.

27 (new): The metal complex of claim 26 where the metal is a radiometal.

28 (new): The radiometal complex of claim 27 where the radiometal is <sup>99m</sup>Tc.

29 (new): A preparation for human administration comprising the compound of claim 20.

30 (new): A kit comprising the compound of claim 20 useful in the preparation of metal complexes.